Psychiatric side effects of mefloquine: Applications to forensic psychiatry

Journal of the American Academy of Psychiatry and the Law

Volumn 41, Issue 2, 2013, Pages 224-235

  Cameron Ritchie, Elspeth ^a   Block, Jerald ^b   Lee Nevin, Remington ^c  

^a District of Columbia Department of Health   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; MEFLOQUINE;

AGGRESSION; CHEMICALLY INDUCED; COMORBIDITY; CONTRAINDICATIONS; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; DRUG LABELING; DRUG SURVEILLANCE PROGRAM; EXPERT WITNESS; FORENSIC PSYCHIATRY; HUMAN; LEGAL LIABILITY; LEGISLATION AND JURISPRUDENCE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; SUICIDE; TOXICITY; VIOLENCE; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; DRUG EFFECT; LEGAL ASPECT; MENTAL DISEASE; PSYCHOLOGICAL ASPECT; PSYCHOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGGRESSION; ANTIMALARIALS; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DRUG LABELING; EXPERT TESTIMONY; HUMANS; INSANITY DEFENSE; LIABILITY, LEGAL; MEFLOQUINE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; PSYCHOSES, SUBSTANCE-INDUCED; SUICIDE; VIOLENCE;

EID: 84879173053     PISSN: 10936793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (200)

1. Ohnmacht CJ, Patel AR, Lutz RE: Antimalarials. 7. Bis(trifluoromethyl)-(2-piperidyl)-4-quinolinemethanols. J Med Chem 14:926-8, 1971
2. Maugh TH: Malaria drugs: new ones are available, but little used. Science 196:415, 1977
3. Fernex M: Urgent need to develop new antimalarials (in German). Schweiz Rundsch Med Prax 70:1025-32, 1981
4. Enserink M: Malaria researchers wait for industry to join fight. Science 287:1956-8, 2000
5. Boudreau E, Schuster B, Sanchez J, et al: Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 44:257-65, 1993
6. White NJ: Mefloquine. BMJ 308:286-7, 1994
7. Macarthur JR, Parise ME, Steketee RW: Letter to the Editor. Am J Trop Med Hyg 66:445, 2002
8. Lobel HO, Bernard KW, Williams SL, et al: Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine: need for a better dosing regimen. JAMA 265:361-4, 1991
9. Centers for Disease Control and Prevention (CDC): Change of dosing regimen for malaria prophylaxis with mefloquine. MMWR 40:72-3, 1991
10. Burke BM: Tragic time-lag. New Sci150:51, 1996
11. Dixon KE, Williams RG, Pongsupat T, et al: A comparative trial of mefloquine and fansidar in the treatment of falciparum malaria: failure of fansidar. Trans R Soc Trop Med Hyg 76:664-7, 1982
12. Sweeney TR: The present status of malaria chemotherapy: mefloquine, a novel antimalarial. Med Res Rev 1:281-301, 1981
13. Hall AP: The treatment of malaria. BMJ 1:323-8, 1976
14. Heimgartner E: Practical experience with mefloquine as an antimalarial (in German). Schweiz Rundsch Med Prax 75:459-62, 1986
15. Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, et al: Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 3:83-8, 1998
16. Rab SM: Two cases of chloroquine psychosis. BMJ 1:1275, 1963
17. Rockwell DA: Psychiatric complications with chloroquine and quinacrine. Am J Psychiatry 124:1257-60, 1968
18. Kingsbury AN: Psychoses in cases of malaria following exhibition of Atebrin. Lancet 2:979-87, 1934
19. Mergener JC: Psychosis following administration of quinacrine hydrochloride for malaria; neuropsychiatric study of a case. War Med (Chic 1941) 8:250-52, 1945
20. Lapras J, Vighetto A, Trillet M, et al: Transient disorders of memory after a malaria attack: caused by mefloquine (in French)? Presse Med 18:776, 1989
21. Rouveix B, Bricaire F, Michon C, et al: Mefloquine and an acute brain syndrome. Ann Intern Med 110:577-8, 1989
22. Stuiver PC, Ligthelm RJ, Goud TJ: Acute psychosis after mefloquine. Lancet 2:282, 1989
23. Björkman A: Acute psychosis following mefloquine prophylaxis. Lancet 2:865, 1989
24. Bem JL, Kerr L, Stuerchler D: Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 95:167-79, 1992
25. Lobel HO: Adverse health events and malaria prophylaxis. Healthwise: A Newsletter for Peace Corps Medical Officers Worldwide 5:3-4, 1996
26. Schlagenhauf P: Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J Trav Med 6:122-33, 1999
27. Schlagenhauf P, Steffen R: Neuropsychiatric events and travel: do antimalarials play a role? J Trav Med 7:225-6, 2000
28. Overbosch D, Schilthuis H, Bienzle U, et al: Atovaquoneproguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 33:1015-21, 2001
29. van Riemsdijk MM, Sturkenboom MCJM, Ditters JM, et al: Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. J Clin Pharm Ther 72:294-301, 2002
30. Jacquerioz FA, Croft AM: Drugs for preventing malaria in travelers. Cochrane Database Syst Rev Cd006491, 2009
31. Meier CR, Wilcock K, Jick SS: The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 27:203-13, 2004
32. Weinke T, Trautmann M, Held T, et al: Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45:86-91, 1991
33. Department of the Army Office of the Surgeon General: Memorandum. Subject: Updated health care provider information on use of mefloquine hydrochloride (Lariam®) for malaria prophylaxis. October 3, 2002. Available at http://www.pdhealth.mil/downloads/Mefloquine_Hyrochloride_Use.pdf. Accessed June 13, 2012
34. Department of the Army Office of the Surgeon General: Memorandum. Subject: Updated guidance on use of mefloquine (Lariam®) for malaria prophylaxis. February 2, 2009. Available at https://www.pdhealth.mil/downloads/DASG_Memorandum.pdf. Accessed June 13, 2012
35. Freedman DO: Malaria prevention in short-term travelers. N Engl J Med 359:603-12, 2008
36. Jousset N, Rougé-Maillart C, Turcant A, et al: Suicide by skull stab wounds: a case of drug-induced psychosis. Am J Forensic Med Pathol 31:378-81, 2010
37. Nevin RL: Hallucinations and persecutory delusions in mefloquine-associated suicide. Am J Forensic Med Pathol 33:e8, 2012
38. Javorsky DJ, Tremont G, Keitner GI, et al: Cognitive and neuropsychiatric side effects of mefloquine. J Neuropsychiatry Clin Neurosci 13:302, 2001
39. Peterson AL, Seegmiller RA, Schindler LS: Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine. Case Reports in Psychiatry, 2011. Available at http://www.hindawi.com/crim/psychiatry/2011/350417. Accessed June 13, 2012
40. Nevin RL: Limbic encephalopathy and central vestibulopathy caused by mefloquine: a case report. Travel Med Infect Dis 10: 144-51, 2012
41. Lebain P, Juliard C, Davy JP, et al: Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases (in French). L'Encéphale 26:67-70, 2000
42. Wittes RC, Saginur R: Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ 152:515-17, 1995
43. Burke BM: Mefloquine. Lancet 341:1605-6, 1993
44. Caillon E, Schmitt L, Moron P: Acute depressive symptoms after mefloquine treatment. Am J Psychiatry 149:712, 1992
45. Lysack JT, Lysack CL, Kvern BL: A severe adverse reaction to mefloquine and chloroquine prophylaxis. Aust Fam Physician 27:1119-20, 1998
46. Tran TM, Browning J, Dell ML: Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Maleria J 5:74, 2006
47. Even C, Friedman S, Lanouar K: Bipolar disorder after mefloquine treatment. J Psychiatry Neurosci 26:252-3, 2001
48. Moore TJ, Glenmullen J, Furberg CD: Prescription drugs associated with reports of violence towards others. PloS One 5:e15337, 2010
49. Croft AM, Whitehouse DP, Cook GC, et al: Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf 1:19-27, 2002
50. Croft AM, Herxheimer A: Tolerability of antimalaria drugs. Clin Infect Dis 34:1278, 2002
51. Choo V: Uncertainty about mefloquine will take time to resolve. Lancet 347:891, 1996
52. Thompson C: Malaria pill stands accused. New Sci 150:14-15, 1996
53. Clift S, Grabowski P: Malaria prophylaxis and the media. Lancet 348:344, 1996
54. Consumer Reports: Lariam's Legacy. Consumer Reports. March, 2002, pp 60-1
55. Burton B: Australian army faces legal action over mefloquine. BMJ 329:1062, 2004
56. Bateman C: MCC "tardy" as couple suffer Mefliam "nightmare." S Afr Med J 99:429-31, 2009
57. Larocque RC, Rao SR, Lee J, et al: Global TravEpiNet: a national consortium of clinics providing care to international travelers-analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis 54:455-62, 2012
58. Nevin RL: Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning. Neurotoxicology 32: 986-7, 2011
59. Strauch S, Jantratid E, Dressman JB, et al: Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride. J Pharmaceut Sci 100:11-21, 2011
60. Rathnam PJ, Bryan JP, Wolfe M: Epidemiology of malaria among United States government personnel assigned to diplomatic posts. Am J Trop Med Hyg 76:260-6, 2007
61. Nevin RL, Pietrusiak PP, Caci JB: Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J 7:30, 2008
62. Nevin RL: Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 19:206-10, 2010
63. Office of the Assistant Secretary of Defense for Health Affairs: Memorandum. Subject: Policy memorandum on the use of mefloquine (Lariam®) in malaria prophylaxis. Washington, DC: Department of Defense, September 4, 2009. Available at http://www.health.mil/libraries/HA_Policies_and_Guidelines/09017.pdf. Accessed June 13, 2012
64. Office of the Assistant Secretary of Defense for Health Affairs: Memorandum. Subject: Service review of mefloquine prescribing practices. January 17, 2012. Available at http://truth-out.org/files/Mefloquine-QA-Memo-JAN-2012-(Signed).pdf. Accessed June 13, 2012.
65. Magill AJ, Cersovsky SB, DeFraites RF: Advising travelers with specific needs: special considerations for US military deployments. CDC Health Information for International Travel, Chap 8:2012, July 26, 2011. Available at http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-8-advising-travelers-withspecific-needs/special-considerations-for-us-military-deployments.htm. Accessed June 13, 2012
66. United States Central Command (USCENTCOM): Modification 11 to USCENTCOM Individual Protection and Individual/Unit Deployment Policy. December 2, 2011
67. United States Africa Command: Change 2 to ACM 4200.03. Force health protection procedures for deployment and travel. Notice 4200.02, September 20, 2011
68. Kime P: New concerns rising over antimalaria drug. Army Times, April 11, 2012. Available at http://www.armytimes.com/news/2012/04/military-new-concerns-antimalaria-doxycyclinemefloquine-041112w. Accessed June 13, 2012
69. Milatovic D, Aschner M: Response to Nevin RL: Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning. Neurotoxicology 32:988, 2011
70. Roche: Lariam® (Mefloquine Hydrochloroquine) Medication Guide. Nutley, NJ: F. Hoffman-La Roche, September 2008
71. Schlagenhauf P, Adamcova M, Regep L, et al: The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 9:357, 2010
72. Nevin RL: Mefloquine blockade of connexin 36 and connexin 43 gap junctions and risk of suicide. Biol Psychiatry 71:e1-2, 2012
73. Gascón J, Almeda J, Corominas N, et al: Severe neuropsychiatric reaction following mefloquine use (in Spanish). Med Clin (Barc) 101:515-16, 1993
74. Fuller SJ, Naraqi S, Gilessi G: Paranoid psychosis related to mefloquine antimalarial prophylaxis. P N G Med J 45:219-21, 2002
75. Potasman I, Seligmann H: A unique case of mefloquine-induced psoriasis. J Trav Med 5:156, 1998
76. Clattenburg RN, Donnelly CL: Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine. J Am Acad Child Adolesc Psychiatry 36:1606-8, 1997
77. Colebunders R: Cured of fear of flying. Travel Med Infect Dis 9:82, 2011
78. Tor PC, Lee HY, Tan CH: Mefloquine-induced mania in a 22-year-old Chinese man. Singapore Med J 47:549-50, 2006
79. Meszaros K, Kasper S: Psychopathological phenomena in longterm follow-up of acute psychosis after preventive mefloquinine (Lariam) administration (in German). Nervenarzt 67:404-6, 1996
80. Folkerts H, Kuhs H: Psychotic episode caused by prevention of malaria with mefloquine: a case report. Nervenarzt 63:300-2, 1992
81. Piening RB, Young SA: Mefloquine-induced psychosis. Ann Emerg Med 27:792-793, 1996
82. Eaton L: Adverse reactions. Nurs Times 92:16-17, 1996
83. Thapa R, Biswas B: Childhood mefloquine-induced mania and psychosis: a case report. J Child Neurol 24:1008-9, 2009
84. Kukoyi O, Carney CP: Curses, madness, and mefloquine Psychosomatics 44:339-41, 2003
85. Borruat FX, Nater B, Robyn L, et al: Prolonged visual illusions induced by mefloquine (Lariam): a case report. J Trav Med 8:148-9, 2001
86. De Gennes C, Colas C, Nollet D, et al: Panic attack after therapeutic administration of mefloquine (in French). Ann Med Interne (Paris) 142:631, 1991
87. Nosten F, Imvithaya S, Vincenti M, et al: Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquinesulfadoxine-pyrimethamine. Bull World Health Organ 65:891-896, 1987
88. Briand V, Bottero J, Noël H, et al: Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 200:991-1001, 2009
89. Harinasuta T, Bunnag D, Wernsdorfer WH: A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ 61:299-305, 1983
90. Fiaccadori E, Maggiore U, Rotelli C, et al: Thrombotic-thrombocytopenic purpura following malaria prophylaxis with mefloquine. J Antimicrob Chemother 57:160-1, 2006
91. Loefler I: Mefloquine and anticoagulant interaction. J Trav Med 10:194-5, 2003
92. Oueriagli Nabih F, Touhami M, Laffinti A, et al: Mood disorder after malaria prophylaxis with mefloquine (two case reports) (in French). L'Encéphale 37:393-6, 2011
93. World Health Organization (WHO): Review of central nervous system Adverse events related to the antimalarial drug, mefloquine (1985-1990). WHO/MAL/91.1063, 1991
94. Grupp D, Rauber A, Froscher W: Neuropsychiatric disturbances after malaria prophylaxis with mefloquine (in German). Akt Neurol 21:134-6, 1994
95. Gascón J, Pujol A, Codina C, et al: Side-effects of the antimalarial mefloquine: presentation of 20 cases (in Spanish). Med Clin (Barc) 95:277, 1990
96. Sturchler D, Handschin J, Kaiser D, et al: Neuropsychiatric side effects of mefloquine. N Engl J Med 322:1752-3, 1990
97. Roche: Lariam® (Mefloquine Hydrochloroquine) Medication Guide. Nutley, NJ: F. Hoffman LaRoche, November, 1989
98. Ocko FH: A case of atabrine psychosis in a civilian. Am J Psychiatry 103:833, 1947
99. Loken AC, Haymaker W: Pamaquine poisoning in man, with a clinicopathologic study of one case. Am J Trop Med Hyg 29: 341-52, 1949
100. Quintanilla J: Psychosis due to quinidine intoxication. Am J Psychiatry 113:1031-2, 1957
101. Recasens C, Zittoun C, Féline A: A psychotic episode in a patient coming home from Africa: the possible role of mefloquine (in French). Ann Psychiatr 8:100-3, 1993
102. Croft AM, World MJ: Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet 347:326, 1996
103. Hollweg M, Soyka M, Greil W: Mefloquine-induced psychosesproblems in etiologic classification based on 2 case reports (in German). Psychiatr Prax 22:33-6, 1995
104. Wallace MR, Sharp TW, Smoak B, et al: Malaria among United States troops in Somalia. Am J Med 100:49-55, 1996
105. Barrett PJ, Emmins PD, Clarke PD, et al: Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 313:525-8, 1996
106. Hennequin C, Bourée P, Bazin N, et al: Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Int Med 154:2360-2, 1994
107. Marsepoil T, Petithory J, Faucher JM, et al: Encephalopathy and memory disorders during treatments with mefloquine (in French). Rev Med Intern 14:788-91, 1993
108. Carme B, Nevez G, Peguet C, et al: Neuropsychiatric intolerance during mefloquine prophylaxis.:5 case reports (in French). Med Mal Infect 26:728-9, 1996
109. Vuurman EF, Muntjewerff ND, Uiterwijk MM, et al: Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 50:475-482, 1996
110. Roxo MR, Franceschini PR, Zubaran C, et al: The limbic system conception and its historical evolution. Sci World J 11:2428-41, 2011
111. Mas A: Hepatic encephalopathy: from pathophysiology to treatment. Digestion 73(Suppl 1):86-93, 2006
112. Córdoba J: New assessment of hepatic encephalopathy. J Hepatol 54:1030-40, 2011
113. Anderson NE, Barber PA: Limbic encephalitis: a review. J Clin Neurosci 15:961-71, 2008
114. Kaplan PW, Rossetti AO, Kaplan EH, et al: Proposition: limbic encephalitis may represent limbic status epilepticus-a review of clinical and EEG characteristics. Epilepsy Behav 24:1-6, 2012
115. Alisky JM, Chertkova EL, Iczkowski KA: Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. Med Hypotheses 67:1090-4, 2006
116. Chevli R, Fitch CD: The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob Agents Chemother 21: 581-586, 1982
117. Baudry S, Pham YT, Baune B, et al: Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 49:1086-90, 1997
118. Dow GS, Milner E, Bathurst I, et al: Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. Malar J 10:150, 2011
119. Jones R, Kunsman G, Levine B, et al: Mefloquine distribution in postmortem cases. Forensic Sci Int 68:29-32, 1994
120. Cruikshank SJ, Hopperstad M, Younger M, et al: Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci USA 101:12364-9, 2004
121. Connors BW, Long MA: Electrical synapses in the mammalian brain. Annu Rev Neurosci 27:393-418, 2004
122. Dere E, Zlomuzica A: The role of gap junctions in the brain in health and disease. Neurosci Biobehav Rev 36:206-17, 2012
123. Allison DW, Ohran AJ, Stobbs SH, et al: Connexin-36 gap junctions mediate electrical coupling between ventral tegmental area GABA neurons. Synapse 60:20-31, 2006
124. Lassen MB, Brown JE, Stobbs SH, et al: Brain stimulation reward is integrated by a network of electrically coupled GABA neurons. Brain Res 1156:46-58, 2007
125. Steffensen SC, Bradley KD, Hansen DM, et al: The role of connexin-36 gap junctions in alcohol intoxication and consumption. Synapse 65:695-707, 2011
126. Allison DW, Wilcox RS, Ellefsen KL, et al: Mefloquine effects on ventral tegmental area dopamine and GABA neuron inhibition: a physiologic role for connexin-36 gap junctions. Synapse 65:804-13, 2011
127. Collins GB, McAllister MS: Chloroquine psychosis masquerading as PCP: a case report. J Psychoactive Drugs 40:211-14, 2008
128. Domino EF: Taming the ketamine tiger. 1965. Anesthesiology 113:678-84, 2010
129. Ellison G: The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 20:250-67, 1995
130. Hoaken PN, Stewart SH: Drugs of abuse and the elicitation of human aggressive behavior. Addict Behav 28:1533-54, 2003
131. Dinis-Oliveira RJ, Carvalho F, Duarte JA, et al: Suicide by hanging under the influence of ketamine and ethanol. Forensic Sci Int 202:e23-7, 2010
132. Landtblom AM: The "sensed presence": an epileptic aura with religious overtones. Epilepsy Behav 9:186-8, 2006
133. Dolgoff-Kaspar R, Ettinger AB, Golub SA, et al: Numinous-like auras and spirituality in persons with partial seizures. Epilepsia 52:640-4, 2011
134. Kasper BS, Kasper EM, Pauli E, et al: Phenomenology of hallucinations, illusions, and delusions as part of seizure semiology. Epilepsy Behav 18:13-23, 2010
135. Amabeoku GJ, Farmer CC: Gamma-aminobutyric acid and mefloquine-induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 29:917-21, 2005
136. Singh K, Shanks GD, Wilde H: Seizures after mefloquine. Ann Intern Med 114:994, 1991
137. Ries S: Cerebral spasm during malaria prophylaxis with mefloquine (in German). Dtsch Med Wochenschr 118:1911-12, 1993
138. Potasman I, Beny A, Seligmann H: Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Trav Med 7:5-9, 2000
139. Gee CE, Benquet P, Demont-Guignard S, et al: Energy deprivation transiently enhances rhythmic inhibitory events in the CA3 hippocampal network in vitro. Neuroscience 168:605-12, 2010
140. Behrens CJ, Ul Haq R, Liotta A, et al: Nonspecific effects of the gap junction blocker mefloquine on fast hippocampal network oscillations in the adult rat in vitro. Neuroscience 192:11-19, 2011
141. Bissiere S, Zelikowsky M, Ponnusamy R, et al: Electrical synapses control hippocampal contributions to fear learning and memory. Science 331:87-91, 2011
142. Dalmau J, Gleichman AJ, Hughes EG, et al: Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091-8, 2008
143. Kleyensteuber B, Ruterbusch V, Bennett J, et al: Limbic encephalitis presenting with seizures, anterograde amnesia, and psychosis in a patient seven weeks status post immature ovarian teratoma removal. Mil Med 175:616-18, 2010
144. Miller BL, Cummings JL, McIntyre H, et al: Hypersexuality or altered sexual preference following brain injury. J Neurol Neurosurg Psychiatry 49:867-73, 1986
145. Jiménez-Huete A, Gil-Nagel A, Franch O: Multifocal myoclonus associated with mefloquine chemoprophylaxis. Clin Neuropharmacol 25:243, 2002
146. Besser R, Krämer G: Suspected convulsive side-effect of mefloquine (Lariam) (in German). Nervenarzt 62:760-1, 1991
147. van Essen TA, Van der giessen RS, Koekkoek S, et al: Antimalaria drug mefloquine induces motor learning deficits in humans. Front Neurosci 4:191, 2010
148. Dalmau J, Graus F, Rosenblum MK, et al: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore) 71:59-72, 1992
149. Sakuma H, Sugai K, Sasaki M: Acute nonparaneoplastic limbic encephalitis in childhood: a case series in Japan. Pediatr Neurol 43:167-72, 2010
150. Napadow V, Sheehan JD, Kim J, et al: The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex 23:806-13, 2013
151. Hessén-Söderman AC, Bergenius J, Palme IB, et al: Mefloquine prophylaxis and hearing, postural control, and vestibular functions. J Trav Med 2:66-9, 1995
152. Chester AC, Sandroni P: Peripheral polyneuropathy and mefloquine prophylaxis. Am J Trop Med Hyg 85:1008-9, 2011
153. Dow G, Bauman R, Caridha D, et al: Mefloquine induces doserelated neurological effects in a rat model. Antimicrob Agents Chemother 50:1045-53, 2006
154. Kofi Ekue JM, Phiri DE, Mukunyandela M, et al: Severe orthostatic hypotension during treatment of falciparum malaria. BMJ 296:396, 1988
155. Bhanji A, Atkins C, Karim M: Postural orthostatic tachycardia syndrome: a case report of palpitations and dizziness following prophylactic mefloquine use. Int J Clin Pharmacol Ther 48: 577-581, 2010
156. Hall AP, Doberstyn EB, Karnchanachetanee C, et al: Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria. BMJ 1:1626-8, 1977
157. Speich R, Haller A: Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med 331:57-8, 1994
158. Bien CG, Elger CE: Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 10:529 e38, 2007
159. Nabeshima T, Mouri A, Murai R, et al: Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci 1086:160-8, 2006
160. Ebert U, Brandt C, Löscher W: Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia 43(Suppl 5):86-95, 2002
161. Dow GS, Hudson TH, Vahey M, et al: The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J 2:14, 2003
162. Dow GS, Koenig ML, Wolf L, et al: The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciarum strains. Antimicrob Agents Chemother 48:2624-32, 2004
163. Hood JE, Jenkins JW, Milatovic D, et al: Mefloquine induces oxidative stress and neurodegeneration in primary rat cortical neurons. Neurotoxicology 31:518-23, 2010
164. Richter R: The effect of certain quinoline compounds upon the nervous system of monkeys. J Neuropathol Exp Neurol 8:155-70, 1949
165. Schmidt IG: Effects of pamaquine on the central nervous system. Anat Rec 97:367, 1947
166. Schmidt IG, Schmidt LH: Neurotoxicity of the 8-aminoquinolines; reactions of various experimental animals to plasmocid. J Comp Neurol 91:337-67, 1949
167. Lyle DJ, Schmidt IG: The selective effect of drugs upon nuclei of the oculogyric system. Am J Ophthalmol 54:706-16, 1962
168. Sipe JC, Vick NA, Schulman S, et al: Plasmocid encephalopathy in the rhesus monkey: a study of selective vulnerability. J Neuropathol Exp Neurol 32:446-57, 1973
169. Canadian Department of National Defense (DND): Report of the somalia commission of inquiry: the mefloquine issue. Ottawa, Ontario, Canada: Minister of Public Works and Government Services, 1997. Available at http://www.dnd.ca/somalia/vol5/v5c41e.htm. Accessed June 13, 2012
170. Benjamin M, Olmsted D: Army eyes malaria drug in Bragg killings. UPI.com, August 9, 2002. Available at http://www.upi.com/Top_News/2002/08/09/Army-eyes-malaria-drug-inBragg-killings/UPI-40391028935596. Accessed June 13, 2012
171. Benjamin M, Olmsted D: Ft. Bragg suspect said to be delu sional. UPI.com, August 31, 2002. Available at http://www.upi.com/Top_News/2002/08/31/Ft-Bragg-suspect-said-to-bedelusional/UPI-97421030839085. Accessed June 13, 2012
172. Orth M: Fort Bragg's deadly summer. Vanity Fair, December 2002. Available at http://www.vanityfair.com/politics/features/2002/12/fortbragg200212. Accessed June 13, 2012
173. Benjamin M, Olmsted D: Malaria-drug diagnosis for 'coward' GI. UPI.com, June 4, 2004. Available at http://www.upi.com/Business_News/Security-Industry/2004/06/04/Malaria-drugdiagnosis-for-coward-GI/UPI-40941086385037. Accessed June 13, 2012
174. Benjamin M, Olmsted D: Exclusive: Army surrenders to 'coward' GI. UPI.com, July 16, 2004. Available at http://www.upi.com/Business_News/Security-Industry/2004/07/16/Exclusive-Army-surrenders-to-coward-GI/UPI-51631089996907. Accessed June 13, 2012
175. Hall KM: U.S. army base tries to stop soldier suicides. USA Today, April 25, 2010. Available at http://www.usatoday.com/news/military/2010-04-24-army-suicides_N.htm. Accessed June 13, 2012
176. Lydersen K: Lost to Lariam? Reader, September 24, 2009. Available at http://www.chicagoreader.com/chicago/lost-to-lariam/Content?oid1201006. Accessed June 13, 2012
177. Notte J: Toxic cocktail: army struggles with mental-health care. The Street, September 16, 2010. Available at http://www.thestreet.com/story/10856361/1/toxic-cocktail-army-struggleswith-mental-health-care.html. Accessed June 13, 2012
178. McCarthy JS: Malaria chemoprophylaxis: in war and peace. Med J Aust 182:148-9, 2005
179. Chen LH, Wilson ME, Schlagenhauf P: Prevention of malaria in long-term travelers. JAMA 296:2234-44, 2006
180. Schlagenhauf P, Tschopp A, Johnson R, et al: Tolerability of malaria chemoprophylaxis in non-immune travellers to subSaharan Africa: multicentre, randomised, double blind, four arm study. BMJ 327:1078, 2003
181. Schlagenhauf P, Petersen E: Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev 21:466-72, 2008
182. Franssen G, Rouveix B, Lebras J, et al: Divided-dose kinetics of mefloquine in man. Br J Clin Pharmacol 28:179-84, 1989
183. Schwartz DE, Weber W, Richard-Lenoble D, et al: Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man. Acta Trop 37:238-42, 1980
184. Rozman RS, Canfield CJ: New experimental antimalarial drugs. Adv Pharmacol Chemother 16:1-43, 1979
185. Ajana F, Fortier B, Martinot A, et al: Mefloquine prophylaxis and neurotoxicity: report of a case (in French). Sem Hop Paris 66:918-19, 1990
186. Rønn AM, Bygbjerg IC: Acute brain syndrome after mefloquine treatment (in German). Ugeskr Laeger 156:6044-5, 1994
187. Pham YT, Nosten F, Farinotti R, et al: Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 37:58-61, 1999
188. Schwartz E, Potasman I, Rotenberg M, et al: Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65:189-92, 2001
189. Schlagenhauf P, Steffen R, Lobel H, et al: Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1:485-94, 1996
190. Nevin RL: Pharmacokinetic considerations in the repositioning of mefloquine for treatment of progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg 114:1204-5, 2012
191. Zaigraykina N, Potasman I: Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis (in Hebrew). Harefuah 149:583-4, 2010
192. Aarnoudse AL, van Schaik RH, Dieleman J, et al: MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 80:367-74, 2006
193. Barraud de Lagerie S, Comets E, Gautrand C, et al: Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 141: 1214-22, 2004
194. Riffkin CD, Chung R, Wall DM, et al: Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol 52:1545-52, 1996
195. Potasman I, Juven Y, Weller B, et al: Does mefloquine prophylaxis affect electroencephalographic patterns? Am J Med 112: 147-9, 2002
196. Bernard J, Le Camus J, Sarrouy J, et al: Toxic encephalopathy caused by mefloquine (in French)? Presse Med 16:1654-65, 1987
197. Burgmann H, Winkler S, Uhl F, et al: Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica (in German). Wien Klin Wochenschr 105:61-3, 1993
198. Leong GB, Leisenring, SE, Dean MD: Commentary: Intoxication and settled insanity- unsettled matters. J Am Acad Psychiatry Law 35:183-7, 2007
199. Brueckner RP, Lasseter KC, Lin ET, et al: First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 58:645-9, 1998
200. Croft AM: A lesson learnt: the rise and fall of Lariam and Halfan. JRSocMed100:170-4,2007